Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).
San Diego, CA (PRWEB) January 26, 2009 -- Stemedica Cell Technologies, Inc. announces leading stem cell specialist Dr Nabil Dib, MD as Special Advisor to its Board of Directors. Dr Dib is President of the International Society for Cardiovascular Translational Research (ISCTR) and Director of Cardiovascular and Stem Cell Consultants (CSCC).
"In looking for someone to serve as Special Advisor to the Board, we sought a medical leader who had practical experience in working with the FDA and the research community in advancing therapeutic stem cell solutions. We feel fortunate to have secured an Advisory Relationship with a true leader within the stem cell industry. Dr Nabil Dib has as much extensive research, regulatory and clinical application experience with adult stem therapy as anyone in the United States," said Nikolai Tankovich, MD, PhD, President & Chief Regulatory and Medical Officer of Stemedica.
In accepting the role of Special Advisor, Dr Dib said, "I'm honored to be associated with Stemedica Cell Technologies. As someone who strives to help build this industry, my research tells me that Stemedica stands out as a leader within our sector. Many stem cell research and manufacturing companies make significant progress in the laboratory, but what distinguishes Stemedica is the extent of their clinical research experience."
"With Dr. Dib we get an independent minded, diligent investigator who has the hands on proven experience in advancing stem cell research and technology from bench top to bed side with the highest possible concern for the safety of the patient and the efficacy of the application," said Maynard Howe, PhD, Vice Chairman and CEO for Stemedica.
About Stemedica Technologies, Inc.:
Stemedica Cell Technologies Inc. is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Within the United States, the Company is currently developing regulatory pathways for traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative disease, sight restoration and wound repair. Stemedica is based in San Diego, Calif.
For more information regarding Stemedica Cell Technologies or the Dr. Nabil Dib appointment, contact Dave McGuigan.
# # #
Read the full story at http://www.prweb.com/releases/2009/01/prweb1907844.htm.
Copyright©2009 Vocus, Inc.
All rights reserved